Teva Slapped With €60m Fine Over Unlawful EU Provigil Delay
Fine Closes ‘Pay-For-Delay’ Investigation That Began In 2011
Teva received a “package of commercial side-deals” for agreeing to halt generic competition to Cephalon’s Provigil (modafinil) throughout the EU, which it “would not have achieved without committing to staying out of the market,” according to findings by the European Commission.
You may also be interested in...
A ruling by the EU’s General Court has confirmed that agreements between Servier and several generics firms over perindopril constituted restrictions of competition. However, it has reduced by more than €100 million a fine on Servier and has eliminated entirely a fine on Krka.
After launching in the US last year, the teriparatide product developed by Pfenex and Alvogen has been introduced in Europa, via commercialization partner Theramex, beginning with Germany.
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.